<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Forty patients were enrolled in this phase 2 study combining radioimmunotherapy (RIT) using <z:chebi fb="2" ids="33331">yttrium</z:chebi>-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity conditioning (RIC) using fludarabine (90 mg/m(2)) and 2 Gy total body irradiation followed by allogeneic hematopoietic cell transplantation (HCT) from related (n = 13) or unrelated (n = 27) donors for the treatment of advanced non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Diagnoses were follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 17), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (n = 13), mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 8), marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1), and lymphoplasmacytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1) </plain></SENT>
<SENT sid="2" pm="."><plain>Median age was 55 years (range, 34-68 years) </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were high risk with refractory disease or relapse after preceding autologous HCT </plain></SENT>
<SENT sid="4" pm="."><plain>No additional toxicities attributable to RIT were observed </plain></SENT>
<SENT sid="5" pm="."><plain>Engraftment was rapid and sustained </plain></SENT>
<SENT sid="6" pm="."><plain>Incidences of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> 2-4 and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> were 43% and 53%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Kaplan-Meier-estimated nonrelapse mortality was 45% at 2 years </plain></SENT>
<SENT sid="8" pm="."><plain>Twenty-two of 40 patients (55%) are alive, resulting in a Kaplan-Meier-estimated 2-year survival of 51% for <z:hpo ids='HP_0000001'>all</z:hpo>, 67% for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 49% for <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, and 37% for mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients </plain></SENT>
<SENT sid="9" pm="."><plain>The combined use of RIT with RIC is feasible with acceptable toxicity, even in elderly and heavily pretreated patients </plain></SENT>
<SENT sid="10" pm="."><plain>This study is registered at www.clinicaltrials.gov as #NCT00302757 </plain></SENT>
</text></document>